Schrödinger
VC Fund
New York, United States
Schrödinger is a VC fund in New York focused on Biotechnology and Medical. Schrödinger’s industry-leading computational platform facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas.Schrödinger is deeply committed toinvesting in the science and talent that drive its computational platform. Schrödinger was founded in 1990, has over 700 employees and is engaged with customers and collaborators in more than 70 countries. To learn more visit www.schrodinger.com.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Schrödinger invests in
Stages Schrödinger invests in
Countries Schrödinger invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Pat Lorton
|
|||
Ramy Farid
|
|||
Richard Friesner
|
|||
Yvonne Tran
|
|||
Christopher Brown
|
|||
| See all 7 contacts → | |||
Investment Focus
Industry
- Biotechnology 6 (60%)
- Medical 4 (40%)
- Health Care 4 (40%)
- Therapeutics 2 (20%)
- Pharmaceutical 2 (20%)
Stage
- Seed 3 (30%)
- Series B 3 (30%)
- Series C 2 (20%)
- Series A 1 (10%)
- Venture - Series Unknown 1 (10%)
Country
- United States 4 (40%)
- China 1 (10%)
- Canada 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Pat Lorton
CTO
|
CTO | Total investments: 0 | Find email | |
|
Ramy Farid
President
|
President | Total investments: 1 | Find email | |
|
Richard Friesner
Co-Founder
|
Co-Founder | Total investments: 1 | Find email | |
|
Yvonne Tran
Executive VP, Chief Legal Officer and Corporate Secretary
|
Executive VP, Chief Legal Officer and Corporate Secretary | Total investments: 0 | Find email | |
|
Christopher Brown
Executive Director of Materials Discovery
|
Executive Director of Materials Discovery | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ajax Therapeutics
|
Ajax Therapeutics develops targeted therapies for hematologic cancers, with a focus on treating myeloproliferative neoplasms through precision drug discovery approaches. The company applies computational chemistry and structural biology to design small-molecule therapies that selectively target disease-driving proteins while minimizing off-targeteffects. Its research centers on next-generation inhibitors of the JAK2 protein, a key driver of certain blood cancers, using a differentiated mechanism that binds the Type II conformation of the kinase. This approach aims to improve treatment effectiveness and address limitations of existing therapies that provide symptom relief but do not fully suppress disease progression. It integrates discovery, preclinical research, and clinical development within its operating model, enabling continuous refinement of drug candidates based on biological insights and trial data. It collaborates with research institutions and leverages scientific expertise in oncology and molecular medicine to support development efforts. | $95M / Series C / May 13, 2024 | |
ShouTi
|
ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR. The company develops drugs focused on novel small molecules for multiple unmet medical needs. ShouTi is currently operating in Stealth mode. | $100M / Series B / Oct 20, 2021 | |
Structure Therapeutics
|
Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations inbiologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team’s deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity. | $100M / Series B / Oct 20, 2021 | |
|
Ajax Therapeutics
|
Ajax Therapeutics develops targeted therapies for hematologic cancers, with a focus on treating myeloproliferative neoplasms through precision drug discovery approaches. The company applies computational chemistry and structural biology to design small-molecule therapies that selectively target disease-driving proteins while minimizing off-targeteffects. Its research centers on next-generation inhibitors of the JAK2 protein, a key driver of certain blood cancers, using a differentiated mechanism that binds the Type II conformation of the kinase. This approach aims to improve treatment effectiveness and address limitations of existing therapies that provide symptom relief but do not fully suppress disease progression. It integrates discovery, preclinical research, and clinical development within its operating model, enabling continuous refinement of drug candidates based on biological insights and trial data. It collaborates with research institutions and leverages scientific expertise in oncology and molecular medicine to support development efforts. | $40M / Venture - Series Unknown / Jun 01, 2021 | |
Bright Angel Therapeutics
|
Bright Angel Therapeutics is a developer of novel therapeutics designed to provide treatment of drug-resistant and life-threatening fungal infections. The company's services increases efficacy of current treatments and eradicates drug resistance by targeting the stress responses required by fungi for survival, virulence and drug resistance,enabling users to overcome the frequent emergence of clinical resistance largely responsible for the severe morbidity and mortality associated with infection by diverse fungal pathogens. | Seed / Dec 03, 2019 | |
Morphic Therapeutic
|
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic was created in 2015 with co-founders Polaris Partners, T.A. Springer and Schrödinger, Inc., along with ShangPharma Investment Group. | $80M / Series B / Sep 25, 2018 | |
Nimbus Therapeutics
|
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders. | $65M / Series C / Jun 05, 2018 | |
|
Morphic Therapeutic
|
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic was created in 2015 with co-founders Polaris Partners, T.A. Springer and Schrödinger, Inc., along with ShangPharma Investment Group. | $51.5M / Series A / Jun 30, 2016 | |
|
Morphic Therapeutic
|
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic was created in 2015 with co-founders Polaris Partners, T.A. Springer and Schrödinger, Inc., along with ShangPharma Investment Group. | Seed / Jan 01, 2016 | |
|
Nimbus Therapeutics
|
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders. | Seed / Apr 29, 2010 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Schrödinger invest in?
Schrödinger invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Series B stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Schrödinger?
Public channels for Schrödinger include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Schrödinger?
The team at Schrödinger includes Pat Lorton (CTO), Ramy Farid (President) and Richard Friesner (Co-Founder), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
